BiotechTube

Sodium Fluoride Dentifrice

Pre-clinicalCompleted
0 watching 0 views this week💤 Quiet
23
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Dental Health

Conditions

Dental Health

Trial Timeline

Oct 1, 2009 → Dec 1, 2009

NCT ID
NCT01009554

About Sodium Fluoride Dentifrice

Sodium Fluoride Dentifrice is a pre-clinical stage product being developed by Johnson & Johnson for Dental Health. The current trial status is completed. This product is registered under clinical trial identifier NCT01009554. Target conditions include Dental Health.

Hype Score Breakdown

Clinical
5
Activity
2
Company
10
Novelty
2
Community
1

Clinical Trials (1)

NCT IDPhaseStatus
NCT01009554Pre-clinicalCompleted

Competing Products

20 competing products in Dental Health

See all competitors
ProductCompanyStageHype Score
Test naproxen sodium tablet + Commercial naproxen sodium tablet + Commercial naproxen sodium liquid gels capsule + Placebo tabletJohnson & JohnsonPhase 3
77
Test acetaminophen + Commercial acetaminophen + Commercial ibuprofen + PlaceboJohnson & JohnsonPhase 3
77
Acetaminophen (ACE) (1000 mg) + Commercial ACE (1000 mg) + Commercial Ibuprofen (IBU) (400 mg) + Placebo + Placebo + PlaceboJohnson & JohnsonPhase 2
52
2 mg nicotine gum + 4 mg nicotine gumJohnson & JohnsonApproved
85
Acetaminophen ER + PlaceboJohnson & JohnsonPhase 2
52
acetaminophen Tablet + acetaminophen Caplet + ibuprofen Liquid-filled capsule + Placebo Tablet + Placebo Caplet + Placebo Liquid-filled capsuleJohnson & JohnsonPhase 3
77
Diclofenac potassium + Ibuprofen + Placebo to ibuprofen + Placebo to diclofenac potassiumNovartisPhase 3
77
Placebo; oral + Placebo; oral + ARRY-371797, p38 inhibitor; oral + ARRY-371797, p38 inhibitor; oral + Celecoxib, COX-2 inhibitor; oral + Placebo; oral + ARRY-371797, p38 inhibitor; oralPfizerPhase 2
51
Pregabalin + Alprazolam + PlaceboPfizerPhase 2
51
Prototype (AN0128 Toothpaste)PfizerPhase 1
32
PF-05089771 + PF-05089771 + PF-05089771 + IbuprofenPfizerPhase 2
51
ARRY-371797, p38 inhibitor; oral + Placebo; oral + Placebo; oral + ARRY-371797, p38 inhibitor; oralPfizerPhase 2
51
PF-04531083 + PF-04531083 + IbuprofenPfizerPhase 2
51
Naproxen sodium and caffeine (BAY2880376) + Naproxen sodium (Aleve) + Caffeine + PlaceboBayerPhase 3
74
XPF-001 + placeboXenon PharmaceuticalsPhase 2
49
N1539 + placebo + N1539 + N1539 + MotrinAlkermesPhase 2
49
Comparator: etoricoxib + Comparator: ibuprofen + Comparator: acetaminophen + codeine + Comparator: placeboOrganonPhase 3
72
Full Dose Strength + Quarter dose strength + Half dose strength + Acetaminophen standard dose + Ibuprofen low dose + Ibuprofen high dose + PlaceboAFT PharmaceuticalsPhase 2
44
Maxigesic 325 + Acetaminophen + Ibuprofen + PlaceboAFT PharmaceuticalsPhase 3
69
C16G2 GelArmata PharmaceuticalsPhase 2
44

Other Products from Johnson & Johnson

Fentanyl transdermal therapeutic systemApproved
85
Nicotine Gum + Nicotine PatchApproved
85
galantamineApproved
85
IbrutinibApproved
85
Paliperidone ERApproved
85